A5088148471- Schizophrenia research and treatment
- Mental Health and Psychiatry
- Retinal and Optic Conditions
- Retinal Development and Disorders
- Pharmaceutical studies and practices
- Health Systems, Economic Evaluations, Quality of Life
- Bipolar Disorder and Treatment
- Pharmaceutical Practices and Patient Outcomes
- Epilepsy research and treatment
- Sleep and Wakefulness Research
- Retinal Diseases and Treatments
- Neuroscience and Neuropharmacology Research
- Diabetes Management and Research
- Family Caregiving in Mental Illness
- Obsessive-Compulsive Spectrum Disorders
- Advanced biosensing and bioanalysis techniques
- Treatment of Major Depression
- Ocular Diseases and Behçet’s Syndrome
- Neuroscience of respiration and sleep
- Diet and metabolism studies
- Dementia and Cognitive Impairment Research
- Attention Deficit Hyperactivity Disorder
- Medication Adherence and Compliance
- Parkinson's Disease and Spinal Disorders
- Intensive Care Unit Cognitive Disorders
Janssen (Germany)
2019-2025
Janssen (Belgium)
2018-2022
University of Ferrara
2022
Johnson & Johnson (Germany)
2020
Telio (Norway)
2018
Ankara University
2018
Johnson & Johnson (Sweden)
2018
Janssen Scientific Affairs (United States)
2018
Ospedale San Luigi Gonzaga
2018
University of Turin
2018
Abstract Background/aims X-linked retinitis pigmentosa (XLRP) is considered one of the most severe forms (RP), accounting for 5–15% all RP cases and primarily affecting males. However, real-world humanistic impacts this disease on patients are poorly investigated, especially with respect to burdens faced by varying severities. Methods EXPLORE XLRP-2 was an exploratory, multicentre, non-interventional study. A retrospective chart review conducted collect clinical/demographic data, including...
Paliperidone palmitate 3-monthly (PP3M) formulation is a long-acting, injectable antipsychotic treatment approved in many countries worldwide for the maintenance of adult patients with schizophrenia. This single-arm, open-label, phase IIIb study evaluated efficacy and safety converting schizophrenia stabilized paliperidone 1-month (PP1M) to PP3M naturalistic clinical setting. After screening (days -7 1), were converted from PP1M (50-150 mg eq.) (175-525 eq.), entered 52-week, flexible-dose...
Purpose: Relapse and treatment adherence to paliperidone palmitate once-monthly (PP1M) three-monthly (PP3M) formulations in patients with schizophrenia were evaluated compared using health claims data.Patients Methods: Data (June 2015─June 2018) obtained from the MarketScan ® Multi-State Medicaid Database retrospectively analyzed.Patients aged ≥18 years ≥1 claim for diagnosis prior and/or at index date (i.e., of first PP3M prescription record same month/year as matched PP1M patients)...
Sudden discontinuation from antipsychotic treatment is a common occurrence in patients with schizophrenia. Lower rates of relapse could be expected for discontinuing longer-acting formulations vs their shorter-acting equivalents.To compare and time-to-relapse between the active (analogous to adherent patients) placebo non-adherent real-world) arms three different paliperidone (oral extended release [paliperidone ER], palmitate once monthly [PP1M], [PP3M] long-acting injectables).Data...
To understand the implications of switching from paliperidone palmitate 1-monthly (PP1M) to 3-monthly (PP3M) treatment schizophrenia perspective four key stakeholders: patients, physicians, nurses and carers.This was a cross-sectional, retrospective, non-interventional study comprising one-time questionnaire (PINC-Q) for adult patients (aged ≥18 years) with (International Classification Diseases; ICD-10) their physician, nurse carer. Questionnaires were developed in association patient carer...
X-linked retinitis pigmentosa (XLRP) is a rare, incurable, vision-threatening, genetic disease. In this study, we aimed to reveal the real-world burden of disease from viewpoint retina specialists and geneticists involved directly in XLRP care identify unique insights that may not otherwise be available through typical clinical studies or health economic research. exploratory, cross-sectional study (EXPLORE XLRP-1), (n = 20) 5) France, Germany, Italy, Spain, UK provided anonymized on their...
Reducing the frequency of long-acting injectable antipsychotic medication may reduce carer burden. To evaluate impact reduced on burden in stable patients with schizophrenia. Carer was assessed using Involvement Evaluation Questionnaire (IEQ) within a 52-week, prospective, single-arm, non-randomised, open-label, international, multicentre study evaluating transitioning schizophrenia to paliperidone palmitate 3-monthly (PP3M) from 1-monthly (PP1M). 159 carers completed IEQ (mean [standard...
Purpose: This pragmatic clinical study aimed to assess goal attainment among patients with schizophrenia treated paliperidone palmitate 3-monthly (PP3M) and its relation their level of disability, whether achieved symptomatic remission at the endpoint. Patients Methods: Goal was assessed as a secondary endpoint using Attainment Scaling (GAS) within 52-week, prospective, single-arm, non-randomized, open-label, international, multicenter evaluating impact transitioning stable from 1-monthly...
Negative symptoms in schizophrenia are associated with impairments social and cognitive functioning leading to substantial long-term disability. Available antipsychotic treatments have demonstrated only modest benefit the improvement of negative symptoms.To compare improvements among patients treated paliperidone palmitate 3-month (PP3M) or 1-month (PP1M) long-acting injectable (LAI) formulations.Data from a randomized double-blind (DB), phase-3, non-inferiority study were analyzed....
Paliperidone palmitate 3-monthly (PP3M) is a second-generation, long-acting injectable antipsychotic formulation indicated for the maintenance treatment of adults with schizophrenia first stabilized paliperidone 1-monthly (PP1M). This exploratory post hoc subgroup analysis 52-week, phase 3b REMISSIO study analysed outcomes according to patient age and disease duration in naturalistic clinical setting. Outcomes patients were [<35 years (n = 123) versus ⩾35 182)] [⩽3 72) >3 233)]. The primary...
Negative symptoms of schizophrenia are key predictors long-term disability. It is important to understand whether treatment with long-acting injectable antipsychotics can improve negative symptom psychopathology. Paliperidone palmitate 3-month formulation (PP3M) provides a sustained release paliperidone, permitting significantly extended dosing interval only 4 doses per year in patients schizophrenia. The efficacy PP3M as assessed by relapse rate comparable the paliperidone 1-month (PP1M)....
Poor adherence to antipsychotic treatment in patients with schizophrenia can result recurrent relapses, worsening disease, functional impairment and reduction responsiveness. Long-acting formulations maintain therapeutic plasma levels for longer durations, reducing dosing frequency delaying time relapse compared oral formulations. Consequently, relatively lower rates of be expected on long-acting injectables (LAIs) who have discontinued versus those discontinuing medications the same...